Fortunately, we now have access to cardiovascular outcomes data in tens of thousands of subjects with T2DM treated with the most recent approved therapies for T2DM [sodium-glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor (GLP-1R) agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.